All In MedTech

PMA device

Lotrafilcon A and B Soft Contact Lenses for Daily and Extended Wear

Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed

FDA's data service is rate-limiting requests. Try again in a minute. The numbers below may be missing or incomplete.

FDA decisions

2

PMA pathway

Device trials

99

Naming "Lotrafilcon A"

MAUDE reports

0

Brand "Lotrafilcon A", since 2015

PubMed studies

169

Mentioning "Lotrafilcon A"

AI summary across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.

Product review deck

A slide deck reviewing Lotrafilcon A and B Soft Contact Lenses for Daily and Extended Wear

About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.

  • Executive summary and key facts
  • Technology
  • Clinical evidence and trials
  • Regulatory history and safety
  • Reimbursement, market and competition
  • Risks, outlook and sources

AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.

FDA decisions

The newest 0 of 2 decisions filed under this name.

FDA's records could not be loaded.

Medicare coverage

National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.

How devices get paid for

Clinical trials

Device studies on ClinicalTrials.gov that name "Lotrafilcon A", any status and sponsor, newest update first.

Open in Trial Radar
  • Bozok UniversityAcademic, hospital or other

    NCT07795671 · 40 participants · Start May 2, 2026 · Primary completion Jul 1, 2026

    Device: Acuvue Oasys for Astigmatism; Air Optix for Astigmatism · For: Astigmatism

    Sites: Yozgat, Turkey (Türkiye)

  • Alcon ResearchNot on our public-company list

    NCT05886881 · 505 participants · Start Aug 3, 2023 · Primary completion Apr 15, 2025

    Device: Lotrafilcon B spherical soft contact lenses; Lotrafilcon B spherical soft contact lenses with comfort additive and 3 more · For: Refractive Errors

    Sites: Orlando, Florida; Medina, Minnesota; St Louis, Missouri · 4 sites in all

  • Alcon ResearchNot on our public-company list

    NCT05886894 · 351 participants · Start Aug 8, 2023 · Primary completion Jun 20, 2025

    Device: Lotrafilcon B multifocal soft contact lenses; Comfilcon A multifocal soft contact lenses · For: Refractive Errors

    Sites: San Diego, California; Jacksonville, Florida; Miami, Florida · 8 sites in all

96 more trials with a free account

Adverse event reports (MAUDE)

Reports received since 2015 naming the brand "Lotrafilcon A", and for the whole product code for context.

This brand

0 reports: 0 malfunction, 0 injury, 0 death

Whole product code LPM

0 reports: 0 malfunction, 0 injury, 0 death

Newest reports for this brand

No MAUDE reports name this brand.

All reports in MAUDE Monitor

Recalls

From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.

No recall in FDA's data is linked to these FDA numbers.

Published research

The most relevant PubMed records for "Lotrafilcon A"[tiab]. The summary above synthesizes these.

PubMedGoogle ScholarLiterature search

Other devices of this type

Also filed under product code LPM.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.